Expertise in
13
conditions

Dr. Samir B. Narayan

Radiation Oncology
Trinity Health Ann Arbor Hospital
5301 McAuley Dr, 
Ypsilanti, MI 
Accepting New Patients
Offers Telehealth
Expertise in
13
conditions
Trinity Health Ann Arbor Hospital
5301 McAuley Dr, 
Ypsilanti, MI 

Overview

Samir Narayan is a Radiation Oncologist practicing medicine in Ypsilanti, Michigan.

Dr. Narayan is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Posterior Fossa Tumor.

He is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 31 clinical trials. Dr. Narayan is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MI

Hospital Affiliations

Trinity Health Ann Arbor Hospital
St Joe Mercy Hospital System Livonia
Chelsea Hospital
Trinity Health Oakland Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Trinity Health Ann Arbor Hospital
5301 McAuley Dr, Ypsilanti, MI 48197

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation
Study Phase: Phase 2/Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

21 Total Publications

The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.
Journal: Advances in radiation oncology
Published: January 12, 2026
Similar Doctors
Expertise in
23
conditions
Dr. Daniel R. Wahl
Radiation Oncology
Expertise in
23
conditions
Dr. Daniel R. Wahl
Radiation Oncology
Referral may be required

University Hospital

1500 E Medical Center Dr, Floor B2 C490, 
Ann Arbor, MI 
 (3.8 miles away)
734-936-4300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Wahl is a physician scientist at the University of Michigan specializing in cancers of the central nervous system. His research focuses on the development of new treatment strategies for brain tumors and his laboratory group is especially interested in interactions between radiation and abnormal metabolism in glioblastoma. In the clinic, he cares for a wide variety of patients with both malignant and benign tumors of the central nervous system. Dr. Wahl is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, and Glioma. Dr. Wahl is currently accepting new patients.

Expertise in
11
conditions
Dr. Avraham Eisbruch
Radiation Oncology
Expertise in
11
conditions
Dr. Avraham Eisbruch
Radiation Oncology
Referral may be required

University Of Michigan Medical Center

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (3.8 miles away)
734-936-4300
Languages Spoken:
English

Avraham Eisbruch is a Radiation Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Eisbruch is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Throat Cancer, Laryngeal Cancer, Dry Mouth, and Head and Neck Squamous Cell Carcinoma (HNSCC).

Expertise in
41
conditions
Dr. Inga S. Grills
Radiation Oncology
Expertise in
41
conditions
Dr. Inga S. Grills
Radiation Oncology
Referral may be required
Before you request

Rose Cancer Treatment Center

3577 West 13 Mile Road, Suite Ll, 
Royal Oak, MI 
 (29.4 miles away)
248-551-5490
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Inga Grills is a Radiation Oncologist practicing medicine in Royal Oak, Michigan. Dr. Grills is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Arteriovenous Malformation, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Gamma Knife Radiosurgery. Dr. Grills is board certified in American Board Of Radiology. Dr. Grills is currently accepting new patients.

Frequently Asked Questions about Dr. Samir B. Narayan

How do I make an appointment with Dr. Samir B. Narayan?

You can book an appointment with Dr. Samir B. Narayan by calling their office at 734-712-3456. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Samir B. Narayan a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Samir B. Narayan is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Samir B. Narayan specialize in?

While Dr. Samir B. Narayan is a Radiation Oncology, they have specific expertise in Lung Cancer, Familial Prostate Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Samir B. Narayan participate in research or clinical trials?

Yes. Dr. Samir B. Narayan has published 21 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Samir B. Narayan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Samir B. Narayan accept my insurance?

Dr. Samir B. Narayan accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 734-712-3456 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Narayan's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile